Compare Carnival Corp (CCL) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs Citius Pharmaceuticals Inc — how do they compare? Carnival Corp trades at $27.71 (market cap $39.71B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Carnival Corp is far larger — about 2120.1× Citius Pharmaceuticals Inc's market cap, and Carnival Corp pays a 1.55% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CCL | CTXR | |
|---|---|---|
Market Cap | $39.71B | $18.73M |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $1.82 |
52-Week Low | $23.89 | $0.48 |
Enterprise Value | $63.63B | $14.95M |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $28.99, up 0.69% today, with a bullish technical signal from moving averages and strong support at $28. The stock shows robust fundamentals, with revenue growing to $26.62B in 2025 and net income at $2.76B, while recent quarters have beaten EPS estimates. Analysts maintain a buy consensus with a $35.18 price target, and positive news highlights fleet expansion and sustainability initiatives.
The outlook for CCL is positive, driven by record travel demand, cost control, and debt reduction, offering potential upside to the consensus target. Risks include fuel price volatility, economic sensitivity, and high leverage, though improved cash flow and dividend reinstatement support investor confidence.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
